Get the Weekly Intelligence Brief — top committee picks every Sunday.
NASDAQ · STOCK

Stryker Corporation

SYK Health Care Unknown Updated July 11, 2026
$329.44
52W $281.00 – $404.87
61/100
$125.40B
37.7
0.78
Price History (6M)
AI Committee Verdict
Buy
Conviction: Contested · 60% agreement · 5 analysts
+13.5%
-4.4%
3.10:1
100%
Executive Summary
6 analysts weighed in with 50% agreement on a bullish lean. Portfolio Manager: Portfolio position concentration is currently healthy. Growth Analyst: Growth rate is decelerating quarter over quarter -- the trend line matters more than the level. Overall recommendation: WATCH.
Bull & Bear Case
Bull Case
  • Positive MACD histogram signals bullish momentum.
  • Daily volatility (ATR%) above ~3% is treated as elevated risk.
Bear Case
  • Both daily and weekly trends are bearish — strong multi-timeframe downtrend.
AI Investment Committee
Committee Consensus As of July 11, 2026
Overall Committee Score
61/100
Agreement
60%
Analysts
5
Conviction
Contested
Value Analyst neutral
48 / 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
+ ROE of 15.1% shows genuine earnings power backing the valuation
− P/E of 37.9 is moderate-to-rich
Growth Analyst bearish
38 / 100 · Moderate confidence
Growth story is weak, decelerating, or inconsistent
− Growth rate is decelerating quarter over quarter -- the trend line matters more than the level
Technical Analyst neutral
58 / 100 · High confidence
Mixed or range-bound price action
+ MACD histogram positive -- bullish momentum
Macro Analyst bullish
70 / 100 · Moderate confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ Market regime is bullish (Bull market -- normal position sizing)
News Analyst bullish
66 / 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.27 across 37 articles, 14d)
Portfolio Manager bullish
75 / 100 · Low confidence
The existing book is healthy enough that position-sizing here is a matter of stock selection, not portfolio constraints
+ Portfolio position concentration is currently healthy
Open Full Terminal →
Technical Analysis
RSI (14)
62.1
Neutral
MACD Histogram
1.352
Bullish Momentum
Trend Direction
Sideways
Weekly: Downtrend
Market Structure
Mixed
Support
$315.07
Resistance
$373.99
Bollinger %B
0.80
Inside Bands
Price vs Moving Averages
EMA 9
$324.81 Above
EMA 21
$319.21 Above
EMA 50
$317.73 Above
EMA 200
$340.21 Below
Fundamental Analysis
Valuation
20
Growth
44
Profitability
78
Financial Health
90
Valuation
P/E Ratio 37.7×
P/B Ratio 6.00×
PEG Ratio
Dividend Yield 1.08%
52W High $404.87
52W Low $281.00
Quality & Growth
ROE 1510.0%
ROA 712.0%
Gross Margin 6424.0%
Operating Margin 1966.0%
Revenue Growth YoY +884.0%
Debt / Equity 0.71
AI Fundamental Assessment
P/E ratio of 37.7 (rich relative to a 15-40x range); Price-to-book of 6.0x; Revenue growth (YoY) of 8.8%; EPS growth (YoY) of 16.5%; Return on equity of 15.1%; Return on assets of 7.1%; Net margin of 13.2%; Gross margin of 64.2%; Current ratio of 1.89 (healthy short-term liquidity); Debt-to-equity of 0.71; Most recent quarter missed estimates by 13.7%; EPS growth decelerating (+40.1% -> -41.8% QoQ); Analyst estimates falling over recent quarters
Key Risks
  • Both daily and weekly trends are bearish — strong multi-timeframe downtrend.
This risk summary is generated from quantitative data signals, not qualitative opinion. All investors should conduct their own due diligence. This is not financial advice.
Get the Full SYK Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal → Mobile
Weekly Intelligence Brief
Get the committee's top-scored stocks every Sunday.
Free · No spam · Unsubscribe anytime